Cargando…

Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

BACKGROUND: Cytomegalovirus (CMV) infection and disease (CMV episodes) are global concerns after allogeneic hematopoietic stem cell transplantation (HSCT). They affect survival, both by direct and indirect effects. Due to safety issues of current anti-CMV antivirals, long-term CMV prophylaxis is poo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robin, Christine, Hémery, François, Dindorf, Christel, Thillard, Julien, Cabanne, Ludovic, Redjoul, Rabah, Beckerich, Florence, Rodriguez, Christophe, Pautas, Cécile, Toma, Andrea, Maury, Sébastien, Durand-Zaleski, Isabelle, Cordonnier, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717816/ https://www.ncbi.nlm.nih.gov/pubmed/29207952 http://dx.doi.org/10.1186/s12879-017-2854-2

Ejemplares similares

Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT
por: Leclerc, Mathieu, et al.
Publicado: (2022)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Breakthrough Covid‐19 infections in vaccinated recipients of allogeneic stem cell transplantation
por: Fourati, Slim, et al.
Publicado: (2022)

Molecular Demonstration of a Pneumocystis Outbreak in Stem Cell Transplant Patients: Evidence for Transmission in the Daycare Center
por: Robin, Christine, et al.
Publicado: (2017)

Risk Factors and Scoring System for Predicting Bacterial Resistance to Cefepime as Used Empirically in Haematology Wards
por: El Maaroufi, Hicham, et al.
Publicado: (2015)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

PB2424: ORAL VERSUS INTRAVENOUS ANTI-CMV PREEMPTIVE THERAPY IN ALLOGENEIC STEM CELL TRANSPLANT PATIENTS WITH CMV REACTIVATION: EXPERIENCE FROM NATIONAL CENTER OF BONE MARROW TRANSPLANTATION, TUNISIA.
por: Yosra Kanoun, Rimmel, et al.
Publicado: (2023)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation
por: Henrique Pinto, Cahue, et al.
Publicado: (2016)

A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients
por: Kumar, Lakshin, et al.
Publicado: (2023)

C1 transfer line of LEAR for PS208-HOT nuclei experiment
por: Hémery, J Y
Publicado: (1994)

Histiocytoid Sweet Syndrome Is More Frequently Associated With Myelodysplastic Syndromes Than the Classical Neutrophilic Variant: A Comparative Series of 62 Patients
por: Ghoufi, Lisa, et al.
Publicado: (2016)

CMV Viral Load and Mortality after Hematopoietic Cell Transplantation: A Cohort Study in the Era of Preemptive Therapy
por: Green, Margaret L., et al.
Publicado: (2016)

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2023)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
por: Ahmed-Belkacem, Abdelhakim, et al.
Publicado: (2022)

Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation
por: Widmann, Thomas, et al.
Publicado: (2008)

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
por: Piñana, José Luis, et al.
Publicado: (2019)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Intrathecal cytomegalovirus immunoglobulin for CMV encephalitis post allogeneic stem cell transplantation
por: Pang, Ian, et al.
Publicado: (2022)

From non-preemptive to preemptive scheduling using synchronization synthesis
por: Černý, Pavol, et al.
Publicado: (2016)

Perioperative Comparison of Preemptive and Non-Preemptive Renal Transplant Recipients
por: Aytekin, Sami, et al.
Publicado: (2020)

Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV‐specific T cells
por: McGuire, Helen M, et al.
Publicado: (2020)

RVX 208
Publicado: (2012)

1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Artau, Annette, et al.
Publicado: (2018)

Metabolic Profiling Early Post-Allogeneic Haematopoietic Cell Transplantation in the Context of CMV Infection
por: Rasmussen, Kirstine K., et al.
Publicado: (2023)

Combined Analysis of Early CD4(+) T Cell Counts and CMV Serostatus May Improve CMV Risk Assessment after Allogeneic Hematopoietic Cell Transplantation
por: Leserer, Saskia, et al.
Publicado: (2021)

Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Barkam, Corinna, et al.
Publicado: (2012)

1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants
por: Catho, Gaud, et al.
Publicado: (2018)

Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease
por: Spilleboudt, Chloé, et al.
Publicado: (2021)

Preemptive SARS patents
por: Brickley, Peg
Publicado: (2003)

High ocular CMV copies and mismatched receipts may predict poor visual prognosis in CMV retinitis patients following allogeneic haematopoietic stem cell transplantation
por: Zhang, Yuehong, et al.
Publicado: (2017)

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Ariza-Heredia, Ella J, et al.
Publicado: (2023)

CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation
por: Iglesias, L, et al.
Publicado: (2017)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation
por: Weissinger, E M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bb0batgunlsdso87ikjmjv7vgc